ID   CS-THL1
AC   CVCL_C1GK
SY   Cedars Sinai-Triple-Hit Lymphoma 1
DR   Wikidata; Q114311286
RX   PubMed=25916698;
RX   PubMed=35687491;
CC   Characteristics: Has chromosomal translocation of the MYC, BCL2 and BCL6 genes.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C131913; High grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements
DI   ORDO; Orphanet_480541; High grade B-cell lymphoma with MYC and/or BCL2 and/or BCL6 rearrangement
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   85Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 10-04-25; Version: 5
//
RX   PubMed=25916698; DOI=10.1016/j.leukres.2015.04.003;
RA   Cinar M., Rosenfelt F., Rokhsar S., Lopategui J., Pillai R.K.,
RA   Cervania M., Pao A., Cinar B., Alkan S.;
RT   "Concurrent inhibition of MYC and BCL2 is a potentially effective
RT   treatment strategy for double hit and triple hit B-cell lymphomas.";
RL   Leuk. Res. 39:730-738(2015).
//
RX   PubMed=35687491; DOI=10.1182/bloodadvances.2021006709; PMCID=PMC9631616;
RA   Zhang J.-B., Wang T.-T., Shetty K., Alkan S., Xu S.-L., Gong Q.,
RA   Liu X.-X., Li Y.-P., Hu Z.-S., Huang W.-D., Wendel H.-G., Herrera A.F.,
RA   Pillai R.K., Song J.Y., Chan W.-C.;
RT   "Genetic characterization and drug sensitivity study of newly derived
RT   HGBL double/triple-hit lymphoma cell lines.";
RL   Blood Adv. 6:5067-5071(2022).
//